Publications by authors named "De Zhao Kong"
Objective: To develop a comprehensive framework for selecting outcomes in evaluating the clinical efficacy of Chinese herbal injections and to scientifically select outcomes for the clinical randomized controlled trial (RCT) of Tan-Re-Qing injection intervening AECOPD.
Methods: A comprehensive literature review and consensus methods, including focus groups and Delphi surveys, were utilized.
Results: Literature analysis identified 513 publications, encompassing regulatory guidance, guidelines, expert consensus, and RCTs.
Background: Depression and coronary heart disease (CHD) have common risk mechanisms. Common single nucleotide polymorphisms (SNPs) may be associated with the risk of depression combined with coronary heart disease.
Methods: This study was designed according to the PRISMA-P guidelines.
Ethnopharmacological Relevance: Yi Mai granule (YMG) consists of two classic Chinese medicine formulas used to treat cardiovascular disease for centuries. The Pink1-Mfn2-Parkin pathway, a well-recognized mechanism that mediates mitochondrial autophagy, plays a big part in mitochondrial quality control and the maintenance of heart function. However, the effects of YMG on endothelial dysfunction and mitochondrial autophagy remain unknown.
View Article and Find Full Text PDFObjectives: To assess the benefits and harms of aluminium adjuvants versus placebo or no intervention in randomised clinical trials in relation to human vaccine development.
Design: Systematic review with meta-analysis and trial sequential analysis assessing the certainty of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Data Sources: We searched CENTRAL, MEDLINE, Embase, LILACS, BIOSIS, Science Citation Index Expanded and Conference Proceedings Citation Index-Science until 29 June 2021, and Chinese databases until September 2021.
Objective: To develop and validate Clinical Diversity In Meta-analyses (CDIM), a new tool for assessing clinical diversity between trials in meta-analyses of interventions.
Study Design And Setting: The development of CDIM was based on consensus work informed by empirical literature and expertise. We drafted the CDIM tool, refined it, and validated CDIM for interrater scale reliability and agreement in three groups.
Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.
Cochrane Database Syst Rev
November 2019
Background: Chronic hepatitis B is associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming at reduction of the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, and improving health-related quality of life. The Chinese herbal medicine formula Xiao Chai Hu Tang has been used to decrease discomfort and replication of the virus in people with chronic hepatitis B.
View Article and Find Full Text PDFBackground: Chronic hepatitis B is a liver disease associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming to reduce the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, as well as to improve health-related quality of life. Acupuncture is being used to decrease discomfort and improve immune function in people with chronic hepatitis B.
View Article and Find Full Text PDFRadix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.
Cochrane Database Syst Rev
June 2019
Article Synopsis
- Hepatitis B virus (HBV) infection can cause severe liver issues, including cirrhosis and cancer, and may be complicated by coinfections like HIV, leading to higher mortality and increased stress for patients.
- Radix Sophorae flavescentis, a herbal treatment thought to ease symptoms and inhibit HBV replication, lacks thorough evaluation concerning its benefits and potential risks in treating chronic hepatitis B.
- The study aims to compare Radix Sophorae flavescentis with other treatments in randomized clinical trials to determine its effectiveness for patients with chronic hepatitis B and related conditions.
Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.
Cochrane Database Syst Rev
April 2019
Article Synopsis
- Hepatitis B virus (HBV) can lead to severe liver issues and associated health risks, especially in people also infected with HIV or other hepatitis types, creating significant health and economic burdens.
- Radix Sophorae flavescentis is an herbal remedy believed to alleviate symptoms and inhibit HBV's replication, but its actual effects on patient outcomes haven't been thoroughly studied.
- The objective of the study is to determine the benefits and potential harms of Radix Sophorae flavescentis compared to a placebo or no treatment for patients with chronic hepatitis B, through a comprehensive review of existing clinical trials.
Error Matrix Tool to Overview the Validity of Evidence on Radix for Chronic Hepatitis B.
J Altern Complement Med
September 2019
Article Synopsis
- A visual error matrix tool was introduced to assess the validity of evidence for Radix in chronic hepatitis B, aiming to enhance clinical trial design and evidence quality.
- The analysis included 6 meta-analyses and 28 randomized clinical trials, revealing critical issues such as systematic errors at low quality and high risk of bias in randomized trials.
- Key findings indicated significant random errors for all-cause mortality and adverse events, alongside design errors related to participant selection and outcome misuse, highlighting the need for improved research methodologies.